Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,359B 1.67B 1.44B 1.35B 1.23B 2.32B 160B 2.35B 15.87B 6.21B 79.91B 6.27B 6.13B 266B P/E 2026 *
-72.4x
P/E 2027 * -74.4x
Enterprise Value 2,359B 1.67B 1.44B 1.35B 1.23B 2.32B 160B 2.35B 15.87B 6.21B 79.91B 6.27B 6.13B 266B EV / Sales 2026 *
295x
EV / Sales 2027 * 214x
Free-Float
83.34%
Yield 2026 *
-
Yield 2027 * -
07-30 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-28 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-31 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-07 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-01 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-27 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
25-08-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-0.44%
1 week-9.31%
Current month+18.14%
1 month-12.16%
3 months-28.16%
6 months-12.02%
Current year-20.23%
1 week 106,500
Extreme 106500
141,400
1 month 86,600
Extreme 86600
141,800
Current year 86,600
Extreme 86600
217,000
1 year 51,750
Extreme 51750
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 2010-01-31
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 2022-03-27
Director TitleAgeSince
Director/Board Member 61 2019-03-18
Director/Board Member 55 2019-03-18
Chairman 54 2010-01-31
Date Insider Type Main position Quantity % Market Cap.
2/28/25 Fiscal year

Director

30,000 0.1625%
2/28/25 Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-9.31%+104.01%+580.85% 1.67B
-1.90%+11.59%+62.29%+102.60% 71.56B
-3.21%-3.13%+32.57%+60.59% 54.43B
-2.05%-6.65%+0.71%+451.67% 27.59B
-1.27%+9.09%+46.56%+4.13% 23.91B
+1.05%+2.08%-17.46%-12.93% 23.14B
+0.10%+7.99%+41.01%-20.48% 18.65B
+3.81%+16.28%+270.78%+488.06% 18.64B
-0.95%+2.46%+24.40%+574.22% 16.01B
+1.24%-1.84%+33.13%+138.10% 12.54B
Average -0.36%+0.79%+59.80%+236.68% 26.81B
Weighted average by Cap. -1.12%+1.59%+51.29%+162.27%

Financials

2026 *2027 *
Net sales 8B 5.66M 4.89M 4.59M 4.18M 7.85M 541M 7.98M 53.82M 21.04M 271M 21.25M 20.79M 901M 11B 7.78M 6.72M 6.32M 5.74M 10.8M 744M 10.98M 74M 28.93M 373M 29.22M 28.58M 1.24B
Net income -31B -21.93M -18.94M -17.8M -16.19M -30.43M -2.1B -30.94M -209M -81.54M -1.05B -82.34M -80.55M -3.49B -30B -21.22M -18.33M -17.22M -15.67M -29.45M -2.03B -29.94M -202M -78.91M -1.02B -79.68M -77.95M -3.38B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
26-08-13 112,000.00 -0.44% 274,197
26-08-13 ₩112,500.00 -0.88% 470,878
26-08-12 ₩113,500.00 -13.95% 624,868
26-08-11 ₩131,900.00 -4.28% 317,931
26-08-10 ₩137,800.00 +13.70% 403,251
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock